Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay.

Saved in:

Bibliographic Details
Title:	Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay.
Authors:	Ji J; Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Zhang Y; Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Redon CE; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America., Reinhold WC; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America., Chen AP; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America., Fogli LK; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America., Holbeck SL; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America., Parchment RE; Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Hollingshead M; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America., Tomaszewski JE; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America., Dudon Q; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America., Pommier Y; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America., Doroshow JH; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America., Bonner WM; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.
Source:	PloS one [PLoS One] 2017 Feb 03; Vol. 12 (2), pp. e0171582. Date of Electronic Publication: 2017 Feb 03 (Print Publication: 2017).
Publication Type:	Journal Article
Journal Info:	Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1932-6203
DOI:	10.1371/journal.pone.0171582